BioNTech Boosts 2025 Outlook as Cancer Drug Alliance with Bristol Myers Squibb Takes Aim at Merck’s Keytruda

Germany’s BioNTech SE has raised its 2025 revenue outlook after receiving the first tranche of payments from its new multi-billion-dollar partnership with Bristol Myers Squibb, a move that marks a major step in its strategic pivot from COVID-19 vaccines to oncology. The Mainz-based biotechnology company, which rose to global prominence for co-developing the Pfizer-BioNTech COVID-19

Read More